WO2004013176A1 - Verfahren zur reinigung von preproinsulin - Google Patents
Verfahren zur reinigung von preproinsulin Download PDFInfo
- Publication number
- WO2004013176A1 WO2004013176A1 PCT/EP2003/007820 EP0307820W WO2004013176A1 WO 2004013176 A1 WO2004013176 A1 WO 2004013176A1 EP 0307820 W EP0307820 W EP 0307820W WO 2004013176 A1 WO2004013176 A1 WO 2004013176A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gly
- leu
- glu
- ser
- gln
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Definitions
- Type 1 diabetes mellitus which is characterized by inadequate production of the hormone insulin by the body.
- the substitution of the missing endocrine insulin secretion by the application of insulin preparations is the only possible form of therapy.
- Insulin preparations are pharmaceutical preparations that contain the hormone insulin as an active ingredient. Not only naturally occurring insulins are used, but also insulin analogues and insulin derivatives.
- the human insulin produced in the human pancreas is a polypeptide consisting of 51 amino acid residues, which are distributed over 2 peptide chains: the A chain with 21 amino acid residues and the B chain with 30 amino acid residues.
- the sequence of the amino acid residues in both peptide chains is genetically determined and known. Both chains are linked by two disulfide bridges. In addition, there is an intrachainar disulfide bridge in the A chain.
- Insulin analogs differ from human insulin by substituting at least one amino acid residue and / or adding or removing at least one amino acid residue. Insulin analogs can either occur naturally in species other than human, or they can be made artificially. Insulin derivatives contain chemically modified amino acid residues, e.g. contain additional ester or amido groups, but otherwise show the human or an analogous amino acid sequence.
- insulin analogues or insulin derivatives show a modified kinetic effect compared to the unmodified human insulin.
- human insulin and the insulin analogues or insulin derivatives have been produced by recombinant DNA technology.
- a corresponding precursor of formula 1 preproinsulin (PPI) is produced, are produced human insulin or the insulin analogues from the by enzymatic cleavage '.
- PPI preproinsulin
- a genetic engineering process for the production of human insulin consists of the following process steps:
- the amino acid sequence (the A and B chain) is already specified in the corresponding areas of the preproinsulin.
- Proteases such as the enzyme trypsin and, if necessary, the enzyme carboxypeptidase B are used for the enzymatic cleavage of the various preproinsulins.
- Preproinsulin is a protein of formula 1, X
- R 1 a) a hydrogen atom, b) a genetically encodable amino acid residue or c) a peptide with 2 to 15 amino acid residues, R 2 is a genetically encodable amino acid residue and
- residues A1 - A20 correspond to the amino acid sequence of the A chain of human insulin or an insulin analogue and residues B1 - B30 correspond to the amino acid sequence of the B chain of human insulin or an insulin analogue.
- the preproinsulin is preferably a protein of formula 1 in which
- X is a peptide with 35 amino acid residues with the sequence of the C chain of human insulin or monkey insulin, or a peptide with 29 amino acids with the sequence: Arg-Asp-Val-Pro-Gln-Val-Glu-Leu-Gly-Gly-GIy- Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg (SEQ ⁇ Ü NO: 1)
- R 1 is a peptide with 2 to 15 amino acid residues, at the carboxyl end of which
- R 2 represents the amino acid residue Asn or Gly, ⁇ . and residues A1 - A20 correspond to the amino acid sequence of the A chain of human insulin and residues B1 - B30 correspond to the amino acid sequence of the B chain of human insulin or an insulin analogue in which Lys instead of Asn in the B3 position and in the B29 position Glu instead of Lys.
- preproinsulin is produced in this process stage in a concentration of approx. 0.5 to 1 g / L and in addition approx.
- the polymeric preproinsulins are among the higher molecular weight fractions. It has surprisingly been found in the context of this invention that the polymeric forms of the preproinsulins negatively influence the stability of the insulins in the subsequent process stages by inducing the denaturation of the native insulins. It is known that during the denaturation reaction chain, in a first reversible step, the dissolved monomeric insulin molecules form linear aggregates in which the repeating units are held together by physical adhesive forces. In an irreversible subsequent reaction, stable, insoluble aggregate bundles (fibrils) arise from the dissolved aggregates, which in turn induce the denaturation of native insulins in an autocatalytic process.
- insoluble insulin fibrils are not only biologically inactive, but can also lead to the clogging of injection needles when the pharmaceutical insulin preparations are applied. In addition, they are also held responsible for immunological intolerance reactions that can occasionally occur during therapy with insulin preparations (J.Brange et al, J. Pharm. Sc. 1997, 86, 517-525; RE Ratner et al., Diabetes, 39, 728-733, 1990).
- the preproinsulin is converted into human insulin using the enzymes trypsin and carboxypeptidase B (see Kemmler, W., Peterson, JD, and Steiner, DF, J. Biol. Chem., 246 (1971) 6786 -6791).
- the connection peptide between the A and B chain (X in Formula 1) and the pret part at the amino end of the B chain (R 1 in Formula 1) are split off.
- trypsin not only are those peptide bonds cleaved whose cleavage leads to human insulin, but in a competing reaction also other peptide bonds whose cleavage leads to several undesirable by-products.
- a cation exchange resin With a cation exchange resin, the higher molecular fractions were separated down to approx. 1%, but the binding capacity of the resin for the preproinsulin proved to be unsatisfactory.
- the present invention therefore relates to a method for effectively separating the High molecular weight substances from an aqueous solution of the preproinsulin with simultaneous high concentration of the monomeric preproinsulin.
- a dilute aqueous solution of a preproinsulin as it arises during the production process of insulin, is at pH 7.0 to 9.0, preferably at pH 7.5 to 8.5 and a conductivity of 5 to 7 mS / cm over a Guard column pumped with an anion exchange resin, e.g. Source 30 Q, is filled.
- the monomeric preproinsulin is not bound to the resin, but runs through the column with the permeate.
- the majority of the higher molecular substances, including the polymeric preproinsulin is adsorbed on the resin and thus separated from the preproinsulin.
- the permeate of this precolumn which contains valuable substances, is adjusted to pH 3.0 to 5.5, preferably to pH 4.0 to 5.0, in hydrochloric acid and then pumped directly onto a second column which is coated with a cation exchange resin, e.g. Source 30 S, is filled.
- the preproinsulin is adsorbed onto this resin and impurities are flushed out of the column with the permeate.
- the preproinsulin is desorbed with the aid of an elution buffer which contains sodium chloride with a linearly increasing concentration of 1 to 20 g / L, preferably 2.5 to 15.0 g / L.
- the purified preproinsulin is collected in a main fraction, whereas other impurities are separated in a pre and post fraction.
- concentration factor F 20-25.
- the higher molecular weight substances were separated apart from ⁇ 0.1%.
- the preproinsulin purified in this way can be isolated from the solution by crystallization or the solution • can be fed directly to the process step of the enzymatic cleavage.
- the invention thus relates to a process for the chromatographic purification of preproinsulin of the formula 1, (B1) (B7) (B19) (B30)
- R 1 a a hydrogen atom, b) a genetically encodable amino acid residue or c) a peptide with 2 to 15 amino acid residues,
- R is a genetically encodable amino acid residue and and residues A1 - A20 correspond to the amino acid sequence of the A chain of human insulin or an insulin analogue and residues B1 - B30 correspond to the amino acid sequence of the B chain of human insulin or an insulin analogue;
- preproinsulin can have the following amino acid sequence:
- Another object of the invention is a method as described above for the separation of foreign substances from the solutions of preproinsulins which induce the denaturation of insulin.
- Another object of the invention is a method as described above, characterized in that the second chromatography is carried out at a pH of 3.0 to 5.5.
- Another object of the invention is a method as described above, characterized in that the second chromatography is carried out at a pressure of 1 to 30 bar.
- Another object of the invention is a method for producing insulin by expression of unfolded preproinsulin, comprising the steps: a) fermentation of genetically modified microorganisms which express unfolded preproinsulin b) harvesting of the microorganisms and cell disruption c) isolation of the inclusion bodies with undissolved, unfolded preproinsulin d) Dissolving the preproinsulin with correct folding of the peptide chain and simultaneously closing the disulfide bridges to preproinsulin and then going through a process for the chromatographic purification of preproinsulin of the formula 1 as described above. e) Enzymatic cleavage of preproinsulin to human insulin f) Cleaning human insulin g) Crystallization of human insulin and drying
- inclusion bodies were formed in the E. coli cells which contained the fusion protein with the amino acid sequence of the preproinsulin.
- the cells were isolated by centrifugation and disrupted by the usual high-pressure homogenization (process stage b).
- the insoluble inclusion bodies released in the process were isolated by centrifugation and washed on the centrifuge with water (process stage c).
- the fusion protein inclusion bodies were in an 8 M
- Guanidine hydrochloride solution dissolved at pH 10.8. After dilution with water and addition of cysteine hydrochloride, the fusion protein was folded at pH 10.8 and 4.degree. C. to close the 3 disulfide bridges to the preproinsulin of the formula 1. The solution was then adjusted to pH 5 with 10% hydrochloric acid and foreign proteins were precipitated, which were separated off by centrifugation.
- Centrifuge supernatant contained 0.6 to 0.8 g / L of monomeric preproinsulin.
- the purity of the preproinsulin was determined by the HPLC-RP analysis to be about 65 area%.
- the HPLC-GPC analysis determined a proportion of approx. 45 area% higher molecular impurities.
- the quotient was formed from the peak area of the preproinsulin in the analysis sample and the corresponding peak area of a standard substance. For the determination of the degree of purity, the quotient was formed from the peak area of the preproinsulin and the sum of the peak areas of all elutable substances in the analysis sample.
- the quotient was formed from the peak areas of all higher molecular weight substances that eluted before the monomeric preproinsulin and the sum of the peak areas of all elutable substances.
- the retention time for the monomeric preproinsulin was determined using a standard substance.
- This preproinsulin corresponds to Formula 1, where is
- R1 a peptide chain with 10 amino acid residues with the sequence:
- Human insulin B1-B30 peptide chain with the sequence of the B chain from human insulin An apparatus was used to purify the preproinsulin solution, which mainly consisted of two chromatography columns arranged in series and a stirring vessel arranged between them. The pH of the solution between the two columns was changed inline in the stirred vessel.
- the solutions used had the following composition: Feed solution for column 1: starting solution 8.0 L (centrifuge supernatant) sodium chloride solution 25% 100 ml ml / L (w / w) 12.5 sodium hydroxide solution 10% (w / w) approx. 4.5 ml ml / L
- the permeate fraction of the first column was in the intermediate vessel (nominal volume: 4 L, equipped with a stirrer, pH probe, and inlet tube) is set in line with 90% lactic acid to pH 3.5 and then pumped directly to the second chromatography column 15th
- the chromatography on the cation exchanger was operated in the adsorption mode, i.e.
- the valuable substance preproinsulin was adsorbed onto the gel during the product application and (after the feed solution had been displaced) was desorbed again with the elution buffer A / B.
- a linearly increasing sodium chloride gradient was used in the elution buffer.
- Displacement buffer for column 2 Purified water 1 L lactic acid 90% 8.3 ml moI / L
- Elution buffer A is identical to the displacement buffer for column 2.
- This preproinsulin corresponds to Formula 1, where is
- X is a peptide chain with 35 amino acid residues with the sequence of
- An apparatus was again used to purify the preproinsulin solution, which mainly consisted of two chromatography columns arranged in series and a stirring vessel arranged between them. The pH of the solution between the two columns was changed inline in the stirred vessel.
- the apparatus for the second chromatography stage was designed to be pressure-stable.
- the chromatography on the cation exchanger was operated in the adsorption mode, i.e.
- the valuable substance preproinsulin was adsorbed onto the gel during the product application and (after the feed solution had been displaced) was desorbed again with the elution buffer A / B.
- a linear sodium chloride gradient in the elution buffer was used to achieve an optimal cleaning effect.
- Feed solution for column 2 permeate fraction of column 1 approx. 10.2 L lactic acid 90% 12.2 ml 1, 2 ml / L pH 4.6
- Elution buffer A is identical to the displacement buffer for column 2.
- Elution buffer B for column 2 Purified water 1 L lactic acid 90% 8.3 ml mol / L
- a solution of preproinsulin with the following amino acid sequence is obtained from the correspondingly genetically modified E. coli cells: Ala-Thr-Thr-Ser-Thr-Gly-Asn-Ser-Ala-Arg-Phe-Val-Lys-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu- Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Glu-Thr- Arg- Asp-Val-Pro-Gln-Val-Glu-Leu-Gly-Gly- Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu- Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-Gly-Ile-
- This preproinsulin corresponds to Formula 1, where is
- X is a peptide chain with 29 amino acid residues with the sequence: Arg-Asp-Val-Pro-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-
- Human insulin B1-B30 peptide chain with an analogous sequence to the B chain of human insulin i.e. with an exchange of Lys for Val in position B3 and an exchange of Glu for Lys in position B29.
- the same apparatus used in Example 1 was used to clean the preproinsulin solution.
- the anion exchange resin Source 30 Q (manufacturer: Pharmacia Biotech; product no .: 17-1275-04) was used for the chromatography on column 1.
- the anion exchange resin Source 30 Q manufactured by Pharmacia Biotech; product no .: 17-1275-04
- twice the amount of regeneration solution compared to Examples 1 and 2 was used.
- Example 2 The change in pH in the intermediate vessel was also carried out as described in Example 1.
- the second chromatography was carried out this time at a working pressure of 15 bar. All other parameters of the second chromatography were the same as described in Example 2.
- the denaturation test (Table 1) shows that the higher molecular weight polymeric forms of preproinsulins, such as those formed during the folding reaction, can induce the denaturation of native insulin.
- the solution was filtered through a membrane filter with a pore size of 0.1 ⁇ m.
- the various test substances were added to this acidic standard solution in the denaturation test: the washing fraction of column 1, which contained the separated polymeric forms of preproinsulins in a concentration of 5 g / L, or the main fraction of column 2, which contained the purified preproinsulin in a concentration of 15 or 17 g / L contained.
- the addition of 10 ml of 0.1% aqueous solution of Poloxamer 171 served as further proof that the observed phenomena were caused by the denaturation of insulin. It is known that Poloxamer 171 can suppress the denaturation of insulin at hydrophobic interfaces (H. Thurow and K. Geisen, Diabetologia (1984) 27, 212-218 and EP 0 018 609).
- the solutions were then heated to 26 ° C. and adjusted to pH 6.1 with 10% sodium hydroxide solution while stirring, the insulin precipitating amorphously.
- the amorphous suspension was stirred at 26 ° C for 50 hours. After this time, insulin crystals were formed in all batches.
- each batch was divided into two roughly equal parts. The first part was placed in a 250 ml measuring cylinder to investigate the sedimentation behavior, the volume of the sediment and the clarity of the supernatant being assessed after standing for 60 minutes at room temperature. The second part was adjusted to pH 3 with 1N hydrochloric acid, the clarity of the resulting solution being assessed after the insulin crystals had dissolved.
- Example 2 from Example 2 contained 17 g / L preproinsulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK03766211T DK1527097T3 (da) | 2002-08-01 | 2003-07-18 | Fremgangsmåde til rensning af preproinsulin |
BR0313131-9A BR0313131A (pt) | 2002-08-01 | 2003-07-18 | Processo para a purificação de preproinsulina |
CA2493539A CA2493539C (en) | 2002-08-01 | 2003-07-18 | A method for purifying preproinsulin |
AU2003254375A AU2003254375B2 (en) | 2002-08-01 | 2003-07-18 | Method for purifying preproinsulin |
MXPA05001042A MXPA05001042A (es) | 2002-08-01 | 2003-07-18 | Un metodo para purificar preproinsulina. |
JP2004525238A JP4519646B2 (ja) | 2002-08-01 | 2003-07-18 | プレプロインスリンの精製方法 |
DE50309087T DE50309087D1 (de) | 2002-08-01 | 2003-07-18 | |
EP03766211A EP1527097B1 (de) | 2002-08-01 | 2003-07-18 | Verfahren zur reinigung von preproinsulin |
SI200331119T SI1527097T1 (sl) | 2002-08-01 | 2003-07-18 | Postopek za ciscenje preproinzulina |
US10/632,414 US20050080000A1 (en) | 2002-08-01 | 2003-08-01 | Method of purifying preproinsulin |
IL166438A IL166438A (en) | 2002-08-01 | 2005-01-23 | Method for purifying preproinsulin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10235168A DE10235168A1 (de) | 2002-08-01 | 2002-08-01 | Verfahren zur Reinigung von Preproinsulin |
DE10235168.6 | 2002-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004013176A1 true WO2004013176A1 (de) | 2004-02-12 |
Family
ID=30128614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007820 WO2004013176A1 (de) | 2002-08-01 | 2003-07-18 | Verfahren zur reinigung von preproinsulin |
Country Status (16)
Country | Link |
---|---|
US (2) | US20050080000A1 (de) |
EP (1) | EP1527097B1 (de) |
JP (1) | JP4519646B2 (de) |
AT (1) | ATE384742T1 (de) |
AU (1) | AU2003254375B2 (de) |
BR (1) | BR0313131A (de) |
CA (1) | CA2493539C (de) |
CY (1) | CY1108046T1 (de) |
DE (2) | DE10235168A1 (de) |
DK (1) | DK1527097T3 (de) |
ES (1) | ES2297223T3 (de) |
IL (1) | IL166438A (de) |
MX (1) | MXPA05001042A (de) |
PT (1) | PT1527097E (de) |
SI (1) | SI1527097T1 (de) |
WO (1) | WO2004013176A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011003944A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und Entfernung von missgefalteten Proteinen/Peptiden |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
PT1196430E (pt) * | 1999-06-29 | 2012-04-18 | Mannkind Corp | Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos |
CA2479751C (en) | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
US7338171B2 (en) * | 2003-10-27 | 2008-03-04 | Jen-Chuen Hsieh | Method and apparatus for visual drive control |
CN101027082A (zh) * | 2004-01-12 | 2007-08-29 | 曼恩坎德公司 | 降低2型糖尿病患者血清胰岛素原水平的方法 |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
US7279457B2 (en) * | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
ES2385934T3 (es) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | Catálisis de la síntesis de dicetopiperazina. |
KR101644250B1 (ko) | 2004-08-23 | 2016-07-29 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
DK1928423T3 (en) | 2005-09-14 | 2016-02-29 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
WO2007041481A1 (en) * | 2005-09-29 | 2007-04-12 | Biodel, Inc. | Rapid acting and prolonged acting insulin preparations |
US8039431B2 (en) | 2006-02-22 | 2011-10-18 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
MX2008013165A (es) * | 2006-04-12 | 2009-01-29 | Biodel Inc | Formulaciones de combinacion de insulina de accion rapida y accion larga. |
US20090175840A1 (en) * | 2008-01-04 | 2009-07-09 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
AU2009257311B2 (en) | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
BR122013025625B1 (pt) | 2008-10-17 | 2021-08-03 | Sanofi-Aventis Deutschland Gmbh | Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
JP5667095B2 (ja) | 2009-03-11 | 2015-02-12 | マンカインド コーポレイション | 吸入器の抵抗を測定するための装置、システムおよび方法 |
CA2764505C (en) | 2009-06-12 | 2018-09-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
MY186089A (en) * | 2009-08-11 | 2021-06-21 | Biocon Ltd | Chromatographic processes and purified compounds thereof |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
MY159565A (en) | 2009-11-13 | 2017-01-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
DK2498802T3 (en) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
CN103459417B (zh) | 2011-02-01 | 2018-04-10 | 诺沃—诺迪斯克有限公司 | 胰岛素的纯化 |
CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
CN102219851B (zh) * | 2011-05-09 | 2012-05-30 | 甘李药业有限公司 | 甘精胰岛素结晶的制备方法 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
KR101983982B1 (ko) | 2011-08-29 | 2019-05-30 | 사노피-아벤티스 도이칠란트 게엠베하 | 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
CA2852536A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421795B2 (en) * | 2012-12-17 | 2019-09-24 | Merck Sharp & Dohme Corp. | Process for purifying insulin and analogues thereof |
ES2754388T3 (es) | 2013-03-15 | 2020-04-17 | Mannkind Corp | Composiciones y métodos de dicetopiperazina microcristalina |
EP3517122A1 (de) | 2013-04-03 | 2019-07-31 | Sanofi | Behandlung von diabetes mellitus durch langzeitwirkende formulierungen von insulinen |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
EP3030294B1 (de) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflationsvorrichtung |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
CA2954287C (en) * | 2014-07-08 | 2020-12-22 | Amphastar Pharmaceuticals, Inc. | Methods of preparing inhalable micronized insulin for pulmonary delivery |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10322168B2 (en) | 2016-01-07 | 2019-06-18 | Amphastar Pharmaceuticals, Inc. | High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same |
CN113773392B (zh) * | 2020-06-09 | 2023-04-07 | 宁波鲲鹏生物科技有限公司 | 一种甘精胰岛素的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003550A1 (en) * | 1989-08-29 | 1991-03-21 | Hoechst Aktiengesellschaft | Fusion proteins, their preparation and use |
US5101013A (en) * | 1987-08-11 | 1992-03-31 | Hoechst Aktiengesellschaft | Process for isolating basic proteins from protein mixtures |
WO1999033988A1 (en) * | 1997-12-29 | 1999-07-08 | Chong Kun Dang Corporation | A process for preparing human proinsulin |
WO2001025278A1 (de) * | 1999-10-02 | 2001-04-12 | Aventis Pharma Deutschland Gmbh | C-peptid zur verbesserten herstellung von insulin und insulinanaloga |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
ZA877505B (en) | 1986-10-14 | 1989-05-30 | Lilly Co Eli | Process for transforming a human insulin precursor to human insulin |
JPH0832726B2 (ja) * | 1987-06-08 | 1996-03-29 | 武田薬品工業株式会社 | ラットbFGFおよびその製造法 |
US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
JP2916206B2 (ja) * | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
ATE148710T1 (de) * | 1992-12-02 | 1997-02-15 | Hoechst Ag | Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken |
US5886154A (en) * | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
DE19735711C2 (de) * | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
SI1261622T1 (sl) * | 2000-02-22 | 2007-06-30 | Merck Serono Sa | Preäśiĺ äśeni rekombinantni hlh s specifiäśno bioaktivnostjo in postopek za njegovo preäśiĺ äśenje |
DE10008064B4 (de) * | 2000-02-22 | 2009-07-02 | Siemens Ag | Verfahren zum Anpassen der einem Turbo-Codierer zuzuführenden Datenblöcke und entsprechende Kommunikationsvorrichtung |
-
2002
- 2002-08-01 DE DE10235168A patent/DE10235168A1/de not_active Withdrawn
-
2003
- 2003-07-18 WO PCT/EP2003/007820 patent/WO2004013176A1/de active IP Right Grant
- 2003-07-18 EP EP03766211A patent/EP1527097B1/de not_active Expired - Lifetime
- 2003-07-18 JP JP2004525238A patent/JP4519646B2/ja not_active Expired - Fee Related
- 2003-07-18 ES ES03766211T patent/ES2297223T3/es not_active Expired - Lifetime
- 2003-07-18 DK DK03766211T patent/DK1527097T3/da active
- 2003-07-18 MX MXPA05001042A patent/MXPA05001042A/es active IP Right Grant
- 2003-07-18 DE DE50309087T patent/DE50309087D1/de not_active Expired - Lifetime
- 2003-07-18 BR BR0313131-9A patent/BR0313131A/pt active Search and Examination
- 2003-07-18 PT PT03766211T patent/PT1527097E/pt unknown
- 2003-07-18 CA CA2493539A patent/CA2493539C/en not_active Expired - Fee Related
- 2003-07-18 AU AU2003254375A patent/AU2003254375B2/en not_active Ceased
- 2003-07-18 SI SI200331119T patent/SI1527097T1/sl unknown
- 2003-07-18 AT AT03766211T patent/ATE384742T1/de active
- 2003-08-01 US US10/632,414 patent/US20050080000A1/en not_active Abandoned
-
2005
- 2005-01-23 IL IL166438A patent/IL166438A/en not_active IP Right Cessation
- 2005-12-15 US US11/305,508 patent/US7803763B2/en not_active Expired - Fee Related
-
2008
- 2008-02-18 CY CY20081100198T patent/CY1108046T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5101013A (en) * | 1987-08-11 | 1992-03-31 | Hoechst Aktiengesellschaft | Process for isolating basic proteins from protein mixtures |
WO1991003550A1 (en) * | 1989-08-29 | 1991-03-21 | Hoechst Aktiengesellschaft | Fusion proteins, their preparation and use |
WO1999033988A1 (en) * | 1997-12-29 | 1999-07-08 | Chong Kun Dang Corporation | A process for preparing human proinsulin |
WO2001025278A1 (de) * | 1999-10-02 | 2001-04-12 | Aventis Pharma Deutschland Gmbh | C-peptid zur verbesserten herstellung von insulin und insulinanaloga |
Non-Patent Citations (2)
Title |
---|
COWLEY D J ET AL: "Expression, purification and characterization of recombinant human proinsulin.", FEBS LETTERS. NETHERLANDS 3 FEB 1997, vol. 402, no. 2-3, 3 February 1997 (1997-02-03), pages 124 - 130, XP002257683, ISSN: 0014-5793 * |
LADISCH M R ET AL: "Recombinant human insulin.", BIOTECHNOLOGY PROGRESS. UNITED STATES 1992 NOV-DEC, vol. 8, no. 6, November 1992 (1992-11-01), pages 469 - 478, XP001155556, ISSN: 8756-7938 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011003944A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und Entfernung von missgefalteten Proteinen/Peptiden |
WO2012107567A2 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und entfernung von missgefalteten proteinen/peptiden |
US9316650B2 (en) | 2011-02-10 | 2016-04-19 | Oxprotect Gmbh | Detection and removal of misfolded proteins/peptides |
US10416170B2 (en) | 2011-02-10 | 2019-09-17 | Oxprotect Gmbh | Detection and removal of misfolded proteins/peptides |
Also Published As
Publication number | Publication date |
---|---|
DE50309087D1 (de) | 2008-03-13 |
AU2003254375A1 (en) | 2004-02-23 |
SI1527097T1 (sl) | 2008-04-30 |
JP4519646B2 (ja) | 2010-08-04 |
CA2493539C (en) | 2012-01-31 |
EP1527097A1 (de) | 2005-05-04 |
ATE384742T1 (de) | 2008-02-15 |
US7803763B2 (en) | 2010-09-28 |
ES2297223T3 (es) | 2008-05-01 |
CY1108046T1 (el) | 2013-09-04 |
AU2003254375B2 (en) | 2009-01-08 |
JP2006513978A (ja) | 2006-04-27 |
DK1527097T3 (da) | 2008-05-26 |
US20060183666A1 (en) | 2006-08-17 |
MXPA05001042A (es) | 2005-04-08 |
DE10235168A1 (de) | 2004-02-12 |
US20050080000A1 (en) | 2005-04-14 |
BR0313131A (pt) | 2005-07-05 |
CA2493539A1 (en) | 2004-02-12 |
PT1527097E (pt) | 2008-02-25 |
IL166438A0 (en) | 2006-01-15 |
IL166438A (en) | 2010-11-30 |
EP1527097B1 (de) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1527097B1 (de) | Verfahren zur reinigung von preproinsulin | |
DE60102899T2 (de) | Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen | |
DE69632224T2 (de) | Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer | |
EP1789445B1 (de) | Verfahren zur entfernung von fibronektin aus plasmafraktionen | |
EP0980874B1 (de) | Verbessertes Verfahren zur Gewinnung von Insulinvorläufern mit korrekt verbundenen Cystinbrücken | |
DE69629210T2 (de) | Insulinabkömmlinge | |
EP0763061B1 (de) | Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung | |
DE4435392B4 (de) | Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF | |
DE4405179A1 (de) | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken | |
DD244345A5 (de) | Neue peptide | |
EP1012191B1 (de) | VERFAHREN ZUR GEWINNUNG VON HOCHREINEM vWF ODER FACTOR VIII/vWF-KOMPLEX | |
EP1817338B1 (de) | Herstellung eines von willenbrand faktor-präparates mit hoher spezifischer aktivität | |
DE69822467T2 (de) | Entzündungshemmende peptide des c-reaktiven proteins | |
EP0549915B1 (de) | Neue synthetische Isohirudine mit verbesserter Stabilität | |
EP1789444A1 (de) | Herstellung eines von willebrand faktor-pr[parates unter verwendung von hydroxylapatit | |
DE19858777B4 (de) | Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen | |
EP0622376B1 (de) | Amorphe monosphärische Formen von Insulinderivaten | |
DE4427531A1 (de) | Humanes zirkulierendes beta-Defensin hBD-1 | |
WO1989001485A1 (en) | Purification of raw peptides by preparative medium-pressure liquid chromatography | |
FLINN et al. | Synthesis and biological characterisation of a series of iberiotoxin analogues | |
DE19513784A1 (de) | Hochreines Urodilatin und Verfahren zu seiner Herstellung | |
WO2004039978A2 (de) | Humanes chondroosteomodulin (tig2), herstellung und verwendung zur behandlung oder diagnose von knochen- und knorpelerkrankungen, fettsucht sowie entzündlichen erkrankungen und hauterkrankungen | |
WO2000017240A1 (de) | Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 166370 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003766211 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2493539 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 166438 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001042 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004525238 Country of ref document: JP Ref document number: 2003254375 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2003766211 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003766211 Country of ref document: EP |